Display options
Cite
Rusckowski M, Wang Y, Blankenberg FG, et al. Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 2016;6(1):4doi: 10.1186/s13550-016-0163-1.
Rusckowski, M., Wang, Y., Blankenberg, F. G., Levashova, Z., Backer, M. V., & Backer, J. M. (2016). Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI research, 6(1), 4. https://doi.org/10.1186/s13550-016-0163-1
Rusckowski, Mary, et al. "Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy." EJNMMI research vol. 6,1 (2016): 4. doi: https://doi.org/10.1186/s13550-016-0163-1
Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV, Backer JM. Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 2016 Dec;6(1):4. doi: 10.1186/s13550-016-0163-1. Epub 2016 Jan 16. PMID: 26780081; PMCID: PMC4715132.
Copy Download .nbib Format: NLM
Share it on

EJNMMI Res. 2016 Dec;6(1):4. doi: 10.1186/s13550-016-0163-1. Epub 2016 Jan 16.

Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.

EJNMMI research

Mary Rusckowski, Yuzhen Wang, Francis G Blankenberg, Zoia Levashova, Marina V Backer, Joseph M Backer

Affiliations

  1. Department of Radiology, University of Massachusetts Medical School, Worcester, MA, 01655, USA.
  2. Department of Radiology/MIPS, Stanford University, Palo Alto, CA, 94305, USA.
  3. Current address: Igenica Biotherapeutics, Inc., Burlingame, CA, 94010, USA.
  4. Sibtech, Inc., Brookfield, CT, 06804, USA.
  5. Sibtech, Inc., Brookfield, CT, 06804, USA. [email protected].

PMID: 26780081 PMCID: PMC4715132 DOI: 10.1186/s13550-016-0163-1

Abstract

BACKGROUND: scVEGF/(177)Lu is a novel radiopharmaceutical targeted by recombinant single-chain (sc) derivative of vascular endothelial growth factor (VEGF) that binds to and is internalized by vascular endothelial growth factor receptors (VEGFR). scVEGF/(177)Lu potential as adjuvant and neoadjuvant anti-angiogenic therapy was assessed in metastatic and orthotopic mouse models of triple-negative breast cancer.

METHODS: Metastatic lesions in Balb/c mice were established by intracardiac injection of luciferase-expressing 4T1luc mouse breast carcinoma cells. Mice with metastatic lesions received single intravenous (i.v.) injection of well-tolerated dose of scVEGF/(177)Lu (7.4 MBq/mouse) at day 8 after 4T1luc cell injection. Primary orthotopic breast tumors in immunodeficient mice were established by injecting luciferase-expressing MDA231luc human breast carcinoma cells into mammary fat pad. Tumor-bearing mice were treated with single injections of scVEGF/(177)Lu (7.4 MBq/mouse, i.v), or liposomal doxorubicin (Doxil, 1 mg doxorubicin per kg, i.v.), or with a combination of Doxil and scVEGF/(177)Lu given at the same doses, but two hours apart. "Cold" scVEGF-targeting conjugate was included in controls and in Doxil alone group. The effects of treatments were defined by bioluminescent imaging (BLI), computed tomography (CT), computed microtomography (microCT), measurements of primary tumor growth, and immunohistochemical analysis.

RESULTS: In metastatic model, adjuvant treatment with scVEGF/(177)Lu decreased overall metastatic burden and improved survival. In orthotopic primary tumor model, a combination of Doxil and scVEGF/(177)Lu was more efficient in tumor growth inhibition than each treatment alone. scVEGF/(177)Lu treatment decreased immunostaining for VEGFR-1, VEGFR-2, and pro-tumorigenic M2-type macrophage marker CD206.

CONCLUSIONS: Selective targeting of VEGFR with well-tolerated doses of scVEGF/(177)Lu is effective in metastatic and primary breast cancer models and can be combined with chemotherapy. As high level of VEGFR expression is a common feature in a variety of cancers, targeted delivery of (177)Lu for specific receptor-mediated uptake warrants further exploration.

Keywords: 177Lu; Breast cancer; Metastases; Targeted radiopharmaceutical; VEGF receptors

References

  1. Cancer Treat Rev. 2012 Oct;38(6):673-88 - PubMed
  2. Cancer Cell. 2009 Mar 3;15(3):232-9 - PubMed
  3. Ann Oncol. 2012 Aug;23 Suppl 6:vi35-9 - PubMed
  4. Blood. 2008 Jun 15;111(12 ):5610-20 - PubMed
  5. Trends Pharmacol Sci. 2009 Dec;30(12):624-30 - PubMed
  6. Biochim Biophys Acta. 2014 Aug;1846(1):161-79 - PubMed
  7. Nat Rev Immunol. 2008 Jan;8(1):59-73 - PubMed
  8. Int J Dev Biol. 2011;55(7-9):861-7 - PubMed
  9. Expert Opin Ther Targets. 2012 Jan;16(1):5-13 - PubMed
  10. Science. 2011 Mar 25;331(6024):1565-70 - PubMed
  11. Int J Cancer. 2006 Oct 1;119(7):1519-29 - PubMed
  12. Pharm Res. 2015 Nov;32(11):3746-55 - PubMed
  13. Nat Rev Cancer. 2008 Aug;8(8):592-603 - PubMed
  14. Curr Opin Immunol. 2010 Apr;22(2):231-7 - PubMed
  15. Mol Cancer Res. 2014 Aug;12(8):1100-11 - PubMed
  16. Int J Cancer. 2014 Jun 15;134(12):2772-7 - PubMed
  17. Genes Cancer. 2011 Dec;2(12):1106-16 - PubMed
  18. Crit Rev Immunol. 2012;32(6):463-88 - PubMed
  19. Adv Cancer Res. 2012;114:237-67 - PubMed
  20. Cancer Res. 2011 Jul 15;71(14):4809-20 - PubMed
  21. Nat Rev Cancer. 2013 Dec;13(12):871-82 - PubMed
  22. Curr Cancer Drug Targets. 2012 Jan;12(1):23-43 - PubMed
  23. PLoS Med. 2007 Jun;4(6):e186 - PubMed
  24. Clin Cancer Res. 2012 Jul 15;18(14 ):3961-71 - PubMed
  25. J Nucl Med. 2011 Oct;52(10 ):1630-7 - PubMed
  26. Nat Rev Cancer. 2008 Aug;8(8):618-31 - PubMed
  27. Histopathology. 2012 Sep;61(3):350-64 - PubMed
  28. J Immunol. 2006 Mar 1;176(5):3098-107 - PubMed
  29. Cancer. 2012 Jul 15;118(14):3455-67 - PubMed
  30. Nat Med. 2007 Apr;13(4):504-9 - PubMed
  31. Cancer Cell. 2013 Mar 18;23(3):277-86 - PubMed
  32. Cancer Res. 2011 Nov 15;71(22):7021-8 - PubMed
  33. Cancer Res. 2010 May 1;70(9):3526-36 - PubMed
  34. PLoS One. 2011;6(6):e21467 - PubMed
  35. Cells. 2014 Feb 14;3(1):92-111 - PubMed
  36. J Immunol. 2009 Dec 15;183(12 ):8286-94 - PubMed
  37. J Pathol. 2012 Aug;227(4):404-16 - PubMed
  38. Eur J Cancer. 2010 May;46(8):1323-32 - PubMed
  39. Cancer Res. 2008 Jun 1;68(11):4340-6 - PubMed
  40. Crit Rev Oncog. 2012;17(1):51-67 - PubMed

Publication Types

Grant support